HealthEquity, Inc. (NASDAQ:HQY) is Ashford Capital Management Inc.’s 9th Largest Position

Ashford Capital Management Inc. decreased its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 0.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 305,222 shares of the company’s stock after selling 2,460 shares during the period. HealthEquity makes up about 3.1% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 9th biggest position. Ashford Capital Management Inc.’s holdings in HealthEquity were worth $24,982,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Wasatch Advisors LP raised its position in shares of HealthEquity by 6.6% in the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock valued at $635,065,000 after purchasing an additional 483,269 shares in the last quarter. State Street Corp increased its stake in shares of HealthEquity by 0.8% in the third quarter. State Street Corp now owns 3,131,900 shares of the company’s stock worth $256,346,000 after buying an additional 23,613 shares during the last quarter. Clearbridge Investments LLC raised its holdings in HealthEquity by 1.9% in the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock valued at $204,915,000 after acquiring an additional 43,491 shares in the last quarter. Mackenzie Financial Corp boosted its stake in HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after acquiring an additional 325,906 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in HealthEquity by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,078,977 shares of the company’s stock worth $170,197,000 after acquiring an additional 15,145 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Activity at HealthEquity

In related news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This represents a 13.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock worth $884,517 in the last three months. 2.20% of the stock is owned by company insiders.

HealthEquity Stock Performance

HQY opened at $101.00 on Tuesday. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $92.81 and its 200-day moving average is $83.79. The stock has a market cap of $8.82 billion, a PE ratio of 84.17, a price-to-earnings-growth ratio of 1.57 and a beta of 0.55. HealthEquity, Inc. has a twelve month low of $62.10 and a twelve month high of $105.82.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HQY. JMP Securities restated a “market outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. BTIG Research upped their price objective on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Mizuho began coverage on HealthEquity in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price target on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $109.64.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.